Top Story

Trabectedin improves PFS, not OS, in liposarcoma, leiomyosarcoma

Trabectedin improves PFS, not OS, in liposarcoma, leiomyosarcoma
November 30, 2015

The antitumor drug trabectedin demonstrated superior disease control compared with conventional chemotherapy among patients with advanced liposarcoma and leiomyosarcoma who failed after prior chemotherapy, according to the results of a phase 3 randomized controlled trial.

However, the study failed to meet its primary endpoint of OS.

In the Journals

Surgeons’ knowledge of contralateral prophylactic mastectomy, breast cancer risk varies

November 30, 2015
Nearly 40% of breast surgeons possessed a low level of knowledge about contralateral prophylactic mastectomy, according to a research letter published in JAMA
Meeting News Coverage

Top Takeaways from ASCO: Male breast cancer

November 29, 2015
CHICAGO — The occurrence of male breast cancer following an initial prior malignancy increased, particularly after a hematologic malignancy, 225% in a 38-year…

Israel Cancer Research Fund honors City of Hope provost

November 29, 2015
Steven T. Rosen, MD, provost and chief scientific officer for City of Hope, received a Lifetime Achievement Award from the Israel Cancer Research Fund.The award…
Meeting News Coverage

Top Takeaways from ASCO: Prostate cancer screening

November 28, 2015
CHICAGO — The revised guidelines for prostate cancer screening with PSA testing issued by the U.S. Preventive Services Task Force in 2012 reduced the number of…
More News Headlines »

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Meeting News Coverage Video

HPV vaccination falling short due to providers, not parents

November 22, 2015
More »

The Patient with Pancreatic Cancer

No commercial support for this activity.

Pancreatic cancer only accounts for 3% of cancer cases, but it is the fourth leading cause of cancer-related death…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan morganatic-roan